2025-05-13 - Analysis Report
Okay, here's the analysis of Johnson & Johnson (JNJ) based on the data provided, presented as requested:

## Johnson & Johnson (JNJ) Stock Analysis

**Company Overview:** Johnson & Johnson is a global healthcare company engaged in the research, development, manufacture, and sale of a broad range of products in the healthcare field.

### 1. Performance Analysis

**Key Numbers:**

*   **JNJ Cumulative Return:** 36.63%
*   **S&P 500 (VOO) Cumulative Return:** 93.97%
*   **Absolute Divergence (JNJ - VOO):** -57.3%
*   **Relative Divergence:** 20.2% (This means the current divergence is near the lower end of its historical range relative to the S&P 500).

**Analysis:**

JNJ has significantly underperformed the S&P 500 over the analyzed period. The relative divergence suggests that while the underperformance is substantial, it is positioned in the lower quartile of its historical range. This implies that it is near the worst underperformance relative to S&P 500, compared to the past.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta  | Cap(B) |
|------------|---------|--------|---------|-------|--------|
| 2015-2017  | 33.0%   | 55.5%  | 1.0%    | 0.1   | 274.9  |
| 2016-2018  | 15.0%   | 10.7%  | -6.0%   | -0.0  | 260.8  |
| 2017-2019  | 25.0%   | 10.7%  | -8.0%   | 0.7   | 303.1  |
| 2018-2020  | 20.0%   | 59.4%  | -10.0%  | 0.5   | 335.9  |
| 2019-2021  | 36.0%   | 59.5%  | -25.0%  | 0.4   | 374.3  |
| 2020-2022  | 8.0%    | 61.3%  | -1.0%   | 0.3   | 396.7  |
| 2021-2023  | -17.0%  | 61.3%  | -38.0%  | 0.4   | 362.6  |
| 2022-2024  | -31.0%  | 61.3%  | -51.0%  | 0.3   | 345.2  |
| 2023-2025  | -2.0%   | 69.7%  | -34.0%  | 0.1   | 370.9  |

*   **CAGR:** The Compounded Annual Growth Rate (CAGR) is inconsistent across the periods. The company showed positive CAGR for the period 2015-2021, but it's decreased.
*   **MDD:** MDD (Maximum Drawdown) is the maximum loss from a peak to a trough of a portfolio, before a new peak is attained. From 2015 to 2025, the MDD has generally increased.
*   **Alpha:** Alpha is often considered to represent the value that a portfolio manager adds to or subtracts from a fund's return. The alpha is negative, suggesting underperformance compared to its benchmark.
*   **Beta:** Beta measures the volatility of a stock in relation to the market. Most Beta is lower than 1, suggesting JNJ is generally less volatile than the market.
*   **Cap(B):** Cap(B) represents Market Capitalization in Billions. It shows the general scale and size of the company.

### 2. Recent Price Action

*   **Current Price:** 154.14
*   **Previous Close:** 154.22
*   **Change:** -0.05
*   **5-day Moving Average:** 155.158
*   **20-day Moving Average:** 155.393
*   **60-day Moving Average:** 159.016

**Analysis:** JNJ's current price is slightly down compared to the previous close. All three moving averages (5, 20, and 60-day) are above the current price, indicating a short-term downtrend. The price is below all moving averages, suggesting continued downward pressure.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3676 (Low Risk)
*   **RSI:** 38.75 (Approaching oversold territory)
*   **PPO:** 0.0619
*   **Delta of Relative Divergence (20-day):** -7.3 (Short-term decline)
*   **Expected Return:** -108.1% (Significant underperformance vs. S&P 500 over the long term if current trends continue)

**Analysis:**

*   The MRI indicates low market risk, which suggests JNJ might be relatively stable compared to the broader market.
*   The RSI is approaching oversold levels, which could signal a potential bounce or reversal.
*   The negative change in relative divergence over the past 20 days confirms recent underperformance.
*   The expected return is very negative, raising concerns about the long-term outlook compared to the S&P 500.
*   The minor price change from previousClose indicates minimal volatility in the most recent period.

### 4. Recent News & Significant Events

*   **2025-05-09:** Major business developments, regulatory changes, or market events.
*   **2025-05-11:** Analyst discussions on performance in the context of industry trends and global economic factors.
*   **2025-05-10:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-05-12:** Market experts highlight both risks and opportunities, advising investors to monitor recent news and company announcements.

**Analysis:** Recent news suggests potential volatility and uncertainty surrounding JNJ, driven by business developments, analyst opinions, and market events. Investors should closely monitor news and announcements.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-04-23 | 4.57  | 21.89 B$    |
| 2024-10-23 | 1.12  | 22.47 B$    |
| 2024-07-25 | 1.95  | 22.45 B$    |
| 2024-05-01 | 1.35  | 21.38 B$    |
| 2025-04-23 | 1.35  | 21.38 B$    |

**Analysis:**

The EPS and revenue figures show some volatility over the past few quarters. Revenues have been generally stable, but the EPS numbers have fluctuated widely.

### 6. Financial Information: Revenue and Profitability

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-03-31   | $21.89B    | 66.40%        |
| 2024-12-31   | $22.52B    | 68.35%        |
| 2024-09-30   | $22.47B    | 69.01%        |
| 2024-06-30   | $22.45B    | 69.40%        |
| 2024-03-31   | $21.38B    | 69.55%        |

### Capital and Profitability

| Quarter      | Equity     | ROE      |
|--------------|------------|----------|
| 2025-03-31   | $78.11B    | 14.08%   |
| 2024-12-31   | $71.49B    | 4.80%    |
| 2024-09-30   | $70.16B    | 3.84%    |
| 2024-06-30   | $71.54B    | 6.55%    |
| 2024-03-31   | $70.02B    | 4.65%    |

**Analysis:**

*   **Revenue:** Revenue has shown some variability.
*   **Profit Margin:** Profit margins are high but have decreased slightly over the analyzed quarters.
*   **Equity:** Equity has increased noticeably.
*   **ROE:** Return on Equity (ROE) has improved in the most recent quarter but showed volatility in previous quarters.

### 7. Overall Assessment

Johnson & Johnson (JNJ) is currently underperforming the S&P 500, with a significant divergence in cumulative returns. Recent price action suggests a short-term downtrend, and technical indicators like RSI are approaching oversold levels. Recent news events point to volatility and uncertainty. The company's financials indicate stable revenues, high-profit margins, and growing equity, but fluctuating EPS and ROE. The extremely negative expected return compared to the S&P 500 is a major concern.

**In summary:** JNJ exhibits short-term weakness and has significantly lagged the broader market. While its financial health appears relatively stable, potential investors should closely monitor the company's response to recent events and its ability to improve its long-term performance relative to the S&P 500. The news and analyst commentary suggest a period of transition or challenge that requires careful consideration.
